| [1] |
Aaron I Vinik, Celine Chaya. Clinical presentation and diagnosis of neuroendocrine tumors[J]. Hematology/oncology Clinics of North America, 2015, 30(1)：21-48.
|
| [2] |
Merav Fraenkel, Antongiulio Faggiano, Gerlof D Valk. Epidemiology of neuroendocrine tumors[J]. Frontiers of Hormone Research，2015, 44：1-23.DOI： 10.1159/000381970. |
| [3] |
Daniel Benchimol, Amine Rahili. Tumors of the colon and rectum[J]. La Revue Du Praticien, 2002, 52(10)：1105-1114.
|
| [4] |
宋玉立，陈原稼，陈浩，等．国际上胃肠胰神经内分泌肿瘤两种分期、分级异同的比较和解读[J]. 中华消化杂志，2014，34(2)：136-139.
|
| [5] |
Yao JC, Hassan M, Phan A，et al. One hundred years after "carcinoid" ：epidemiology of and prognostic factors for neuroendocrine tumors in 35825 cases in the united states[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology，2008，26(18)：3063-3072.
|
| [6] |
唐承薇，郭林杰. 我国胃肠胰神经内分泌肿瘤临床现状分析[J]. 中国实用外科杂志，2014，34(6): 490-492.
|
| [7] |
Wan YH，Lin Y，Xue L，et al. Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms：a single－institution analysis (1995－2012) in south china[J]. BMC Endocrine Disorders, 2012，12(1): 30-30.
|
| [8] |
Maxwell JE，Howe JR.Imaging in neuroendocrine tumors: an update for the clinician[J]．International Journal of Endocrine Oncology，2015，2(2)：159-168.
|
| [9] |
Brabander Tessa，Kwekkeboom Dik J，Feelders Richard A，et al. Nuclear medicine imaging of neuroendocrine tumors[J]. Frontiers of hormone research，2015，44: 73-87.DOI： 10.1159/000382059. |
| [10] |
Mouen A Khashab, Elaine Yong, Anne Marie Lennon，et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors[J]. Gastrointestinal Endoscopy, 2011，73(4)：691-696.
|
| [11] |
咎宁，范娟. CT灌注成像在恶性肿瘤临床应用中的进展[J]. 肿瘤预防与治疗，2016，29(1): 59-63.
|
| [12] |
徐志明，曾蒙苏. 胰腺神经内分泌瘤的MRI特点[J]. 解放军医学院学报，2009，30(4): 490-492.
|
| [13] |
李景南，张红杰，陈洁，等. 胃肠胰神经内分泌肿瘤内科诊治若干建议[J]. 中华消化杂志，2014, 34(6): 361-367.
|
| [14] |
Hofman M, Kong G, Neels O, et al.High management impact of Ga－68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours[J]. Journal of Medical Imaging & Radiation Oncology, 2012，56(1): 40-47.
|
| [15] |
中国胃肠胰神经内分泌肿瘤病理专家组．中国胃肠胰神经内分泌肿瘤病理学诊断共识[J]. 中华病理学杂志，2011，40(4): 257-262.
|
| [16] |
Insabato Luigi. An update on the pathology of neuroendocrine tumors[J]. Frontiers in Bioscience，2016，8(1)：1-12.
|
| [17] |
Wang YH, Yang QC, Lin Y, et al. Chromogranin a as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm[J]. Medicine, 2014. 93(27)：32-47.
|
| [18] |
Massironi S, Rossi RE, Casazza G，et al. Chromogranin a in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution[J]. Neuroendocrinology，2014，100(2): 240-249.
|
| [19] |
Panel Members of Standardization for Diagnostic Tumor Pathology. Standardization for diagnostic tumor pathology: gastroenteropancreatic neuroendocrine neoplasm[J]．Zhonghua Bing Li Xue Za Zhi，2017，46(2)：76-78.
|
| [20] |
Khan MS, Kirkwood A, Tsigani T, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors[J]．J Clin Oncol，2013，31(3)：365-372.
|
| [21] |
Frilling A, Modlin IM, Kidd M, et al.Recommendations for management of patients with neuroendocrine liver metastases[J]. Lancet Oncology, 2014，15(1): 18-21.
|
| [22] |
Delle FG, Kwekkeboom DJ，Van Cutsem E, et al. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms[J]. Neuroendocrinology, 2012，95(2): 74-87.
|
| [23] |
Pape UF, Perren A, Niederle B, et al. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno－ileum and the appendix including goblet cell carcinomas[J]. Neuroendocrinology, 2012，95(2): 135-156.
|
| [24] |
O′Toole Dermot，Kianmanesh Reza，Caplin Martyn.ENETS 2016 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update[J]. Neuroendocrinology，2016，103(2)：117-118.
|
| [25] |
楼文晖. 《中国胃肠胰神经内分泌肿瘤专家共识》胰腺神经内分泌肿瘤外科治疗部分解读[J]. 中国实用外科杂志，2014，34(6)：482-483.
|
| [26] |
Turner NC, Strauss SJ, Sarker D, et al.Chemotherapy with 5－fluorouracil, cisplatin and streptozocin for neuroendocrine tumours[J]. British Journal of Cancer, 2010，102(7): 1106-1112.
|
| [27] |
CSCO神经内分泌肿瘤专家委员会．中国胃肠胰神经内分泌肿瘤专家共识[J]. 临床肿瘤学杂志，2013，18(9): 815-832.
|
| [28] |
Oberg K, LambertsSW. Somatostatinanalogues inacromegaly and gastroentero pancreatic neuroendocrine tumours：past，present and future[J]．Endocr Relat Cancer，2016，23(12)：551-566.
|
| [29] |
Oberg K, K vols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for them anagement of neu roendocrinetumors of the gastroenteropancreatic system [J] . A nn On col，2004，15(6)：966-973.
|
| [30] |
Rinke A, Müller HH, Schadebrittinger C. Placebo－controlled, double－blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the promid study group[J]．Neuroendocrinology, 2009, 27(28)：4656-4663.
|
| [31] |
Papaxoinis G, Syrigos K, Saif MW. Novel therapeutic approaches and mechanisms in neuroendocrine tumors：the role of targeted agents[J]. Discov Med，2016，21(117)：391-402.
|
| [32] |
Massironi S，Conte D，Rossi RE.Somatostatinanalogues in functioninggastroenteropancreatic neuroendocrine tumours：literature review，clinical recommendations and schedules[J]. Scand J Gastroenterol，2016，51(5)：513-523.
|
| [33] |
Lee MS，O′Neil BH. Summary of emerging personalized medicine in neuroendocrine tumors: are we on track[J]. Journal of Gastrointestinal Oncology, 2016，7(5): 804-818.
|
| [34] |
Fazio N, Abdel－Rahman O, Spada F, et al. RAF signaling in neuroendocrine neoplasms: from bench to bedside[J]. Cancer Treatment Reviews, 2014. 40(8): 974-979.
|
| [35] |
Jiang X, Cao Y, Li F, et al. Targeting β－catenin signaling for therapeutic intervention in MEN1－deficient pancreatic neuroendocrine tumours[J]. Nature Communications, 2014，5: 58-69.DOI： 10.1038/ncomms6809. |
| [36] |
Sebastian Krug, Benjamin Kuehnemuth, Heidi Griesmann，et al. CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms[J]. Endocrine Related Cancer, 2014, 21(6): 879-890.
|
| [37] |
Fendrich V, Lopez CL, Manoharan J，et al. Enalapril and ass inhibit tumor growth in a transgenic mouse model of islet cell tumors[J]. Endocrine Related Cancer，2014，21(5)：813-824.
|
| [38] |
Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendoendocrine(includingcarcinoid)tumours(NETs)[J]．Gut，2012，61(1)：6-32.
|
| [39] |
Bodei L. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer[J]. Seminars in Nuclear Medicine, 2016，46(3): 225-238.
|
| [40] |
Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non－functional pancreatic neuroendocrine tumors[J]. Neuroendocrinology, 2016, 103(2)：153-171.
|
| [41] |
Sabet A, Ezziddin K, Pape UF, et al. Long－term hematotoxicity after peptide receptor radionuclide therapy with 177lu－octreotate[J]. Journal of Nuclear Medicine, 2013，54(11): 1857-1861.
|
| [42] |
Erhas B, Tuncel M. Renal function assessment during peptide receptor radionuclide therapy[J]. Seminars in Nuclear Medicine, 2016，46(5): 462-478.
|
| [43] |
Jonathan Strosberg, Nancy Gardner, Larry Kvols. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid－gut[J]. Neuroendocrinology, 2009, 89(4)：471-476.
|